[A24-131] Tislelizumab (gastric or gastroesophageal junction adenocarcinoma, HER2-negative) – Benefit assessment according to §35a Social Code Book V
Last updated 01.04.2025
Project no.:
A24-131
Commission:
Commission awarded on 20.12.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adults with HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma and tumour PD-L1 expression with a TAP (Tumour Area Positivity) score ≥ 5%, and
- tumour PD-L1 expression ≥ 1 (combined positive score; CPS) for first-line treatment: added benefit not proven
- tumour PD-L1 expression < 1 (combined positive score; CPS) for first-line treatment: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A24-131
| Project no. | Title | Status |
|---|---|---|
| A24-130 | Tislelizumab (oesophageal squamous cell carcinoma, second line) – Benefit assessment according to § 35a Social Code Book (SGB) V | Commission completed |
| A24-127 | Tislelizumab (non-squamous NSCLC) - Benefit assessment according to §35a Social Code Book (SGB) V | Commission completed |
| A24-126 | Tislelizumab (squamous NSCLC, first line) – Benefit assessment according to §35a Social Code Book (SGB) V | Commission completed |
| A24-128 | Tislelizumab (NSCLC, second line) - Benefit assessment according to § 35a Social Code Book (SGB) V | Commission completed |
| A24-129 | Tislelizumab (oesophageal squamous cell carcinoma, first line) – Benefit assessment according to §35a Social Code Book V | Commission completed |